<生产厂家价格>

坎苯达唑

坎苯达唑用途

坎本唑是治疗人类圆线虫病和[1]最有效的药物之一。

坎苯达唑名称

[ CAS 号 ]:
26097-80-3

[ 中文名 ]:
坎苯达唑

[ 英文名 ]:
Cambendazol

[中文别名 ]:

[英文别名 ]:

Cambenzole
Novazole
Equiben
Camvet
CBDZ
cambendazole
Isopropyl 2-(4-thiazolyl)-5-benzimidazolecarbamate
NOE [French]
Noviben
Bonlam

坎苯达唑生物活性

[ 描述 ]:

坎本唑是治疗人类圆线虫病和[1]最有效的药物之一。

[ 相关类别 ]:

研究领域 >> 感染

信号通路 >> 其他 >> 其他

[参考文献]

[1]. Bicalho SA, et al. Cambendazole in the treatment of human strongyloidiasis. Am J Trop Med Hyg. 1983 Sep;32(5):1181-3.

坎苯达唑物理化学性质

[ 密度 ]:
1.4±0.1 g/cm3

[ 熔点 ]:
212-214℃ (ethyl acetate hexane )

[ 分子式 ]:
C₁₄H₁₄N₄O₂S

[ 分子量 ]:
302.352

[ 精确质量 ]:
302.083740

[ PSA ]:
108.14000

[ LogP ]:
2.90

[ 折射率 ]:
1.694

[ 储存条件 ]:
库房低温通风干燥

坎苯达唑MSDS

坎苯达唑毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DD6538000

CHEMICAL NAME :: 5-Benzimidazolecarbamic acid, 2-(4-thiazolyl)-, isopropyl ester

CAS REGISTRY NUMBER :: 26097-80-3

LAST UPDATED :: 199612

DATA ITEMS CITED :: 12

MOLECULAR FORMULA :: C14-H14-N4-O2-S

MOLECULAR WEIGHT :: 302.38

WISWESSER LINE NOTATION :: T56 BM DNJ GMVOY1&1 C- ET5N CSJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 80480 ug/kg

SEX/DURATION :: female 8-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 60400 ug/kg

SEX/DURATION :: female 8-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 60800 ug/kg

SEX/DURATION :: female 8-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 80800 ug/kg

SEX/DURATION :: female 8-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 348 mg/kg

SEX/DURATION :: female 6-16 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 348 mg/kg

SEX/DURATION :: female 6-16 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 75 mg/kg

SEX/DURATION :: female 21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 75 mg/kg

SEX/DURATION :: female 21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

MUTATION DATA

TYPE OF TEST :: Mutation test systems - not otherwise specified

TEST SYSTEM :: Mammal - domestic Leukocyte

DOSE/DURATION :: 1 mg/L

REFERENCE :: THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 31,505,1976

坎苯达唑安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Warning

[ 危害声明 ]:
H361

[ 警示性声明 ]:
P281

[ 危害码 (欧洲) ]:
Xn

[ 风险声明 (欧洲) ]:
63

[ 安全声明 (欧洲) ]:
36/37

[ 危险品运输编码 ]:
NONH for all modes of transport

[ RTECS号 ]:
DD6538000

坎苯达唑合成路线

坎苯达唑上下游产品

坎苯达唑上游产品

坎苯达唑下游产品

坎苯达唑文献

The Hymenolepis diminuta-golden hamster (Mesocricetus auratus) model for the evaluation of gastrointestinal anticestode activity.

J. Parasitol. 90(4) , 898-9, (2004)

A novel laboratory anticestode assay was developed using Hymenolepis diminuta in the hamster. The commercial anticestode compounds, praziquantel, bunamidine, and niclosamide were active against patent...

Structural requirements for the induction of cytochromes P450 by benzimidazole anthelmintic derivatives in cultured rabbit hepatocytes.

Biochem. Biophys. Res. Commun. 220(3) , 789-94, (1996)

The effect of sulfur-containing benzimidazoles (thiabendazole, 5-hydroxy-thiabendazole, cambendazole) and sulfur-free derivatives (benzimidazole, carbendazim and 5-hydroxycarbendazim) on cytochrome P4...

Controlled tests of activity of several antiparasitic compounds against natural infections of Haemonchus contortus and other helminths in lambs from a flock established in 1962.

Am. J. Vet. Res. 54(3) , 406-10, (1993)

Antiparasitic activity of several compounds was evaluated over a long period (about 25 years) in the same flock of sheep. Haemonchus contortus was of special interest, including its relation to drug r...

更多文献